Soufflé Therapeutics

Executive Summary

Soufflé Therapeutics is a Boston-based private biopharmaceutical company leveraging structure-based drug design and computational chemistry to develop highly selective small molecule inhibitors for challenging oncology and immunology targets. Founded in 2018, the company has raised $200 million and advanced to Phase 2 clinical development. Its pipeline focuses on previously undrugged pathways implicated in cancer progression and immune dysregulation, aiming to address significant unmet medical needs. With a team of 50-200 employees, Soufflé utilizes proprietary discovery platforms to create novel therapeutics with enhanced selectivity and favorable drug-like properties. In the coming year, Soufflé is expected to report initial efficacy and safety data from its lead Phase 2 trials, which could serve as key value inflection points. The company's robust funding and strategic focus on validated but undrugged targets position it for potential partnership opportunities or additional financing to support pipeline expansion. If clinical data are positive, Soufflé could emerge as a leader in precision small molecule therapies for immune-oncology, offering a differentiated approach to existing modalities.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Data Readout for Lead Oncology Candidate65% success
• Q1 2027Strategic Partnership or Licensing Deal for Immunology Program55% success
• Q2 2027Series D Financing Round70% success